Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism

Movement Disorders

Volumn 19, Issue 8, 2004, Pages 885-891

  Foltynie, Thomas ^a   Goldberg, Terry E ^b   Lewis, Simon G J ^a   Blackwell, Andrew D ^c   Kolachana, Bhaskar S ^b   Weinberger, Daniel R ^b   Robbins, Trevor W ^d   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UK   (United Kingdom)

Author keywords

Cognitive; COMT; Parkinson's disease; Phenotype; Polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR STIMULATING AGENT; METHIONINE; VALINE;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DNA POLYMORPHISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENETIC PREDISPOSITION; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; POPULATION RESEARCH; PREFRONTAL CORTEX; PRIORITY JOURNAL; TASK PERFORMANCE;

ADULT; AGED; AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; CONCEPT FORMATION; DEMOGRAPHY; FEMALE; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; VALINE;

EID: 4444264056     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20118     Document Type: Article

References (50)

1. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
2. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115: 1727-1751.
3. Green J, McDonald WM, Vitek JL, et al. Cognitive impairments in advanced PD without dementia. Neurology 2002;59:1320-1324.
4. Shallice T. Specific impairments of planning. Philos Trans R Sue Lond B Biol Sci 1982;298:199-209.
5. Robbins TW. Dissociating executive functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 1996;351:1463-1470.
6. Owen AM, Sahakian B, Hodges JR, Summers BA, Polkey CE, Robbins TW. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. Neuropsychology 1995;9:126-140.
7. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain Epub Dec 2003.
8. Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia 2003; 41:645-654.
9. Baddeley A. Working memory. Science 1992;255:556-559.
10. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125:584-594.
11. Manes F, Sahakian B, Clark L, et al. Decision-making processes following damage to the prefrontal cortex. Brain 2002; 125:624-639.
12. Dagher A, Owen AM, Boecker H, Brooks DJ. Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain 1999; 122(Pt 10): 1973-1987.
13. Egan M, Goldman D, Weinberger D. The human genome: mutations. Am J Psychiatry 2002; 159:12.
14. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-932.
15. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991; 251:947-950.
16. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995;376: 572-575.
17. Bowen FP, Kamienny RS, Burns MM, Yahr M. Parkinsonism: effects of levodopa treatment on concept formation. Neurology 1975;25:701-704.
18. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Ber1) 1992;107:394-404.
19. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988; 111 (Pt 2):299-321.
20. Kulisevsky J, Avila A, Barbanqj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996 119(Pt 6):2121-2132.
21. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38:596-612.
22. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001 11:1136-1143.
23. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 1999;122:1637-1650.
24. Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18) F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001;124:1125-1130.
25. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
26. Egan ME, Goldberg TE, Kolachana BS, et al. Effect of COMT Va1108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922.
27. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-654.
28. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000;20:RC65.
29. 158met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100:6186-6191.
30. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997; 17:8528-8535.
31. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997; 11: 151-162.
32. Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998;42:707-711.
33. Lidow MS, Koh PO, Arnsten AF. DI dopamine receptors in the mouse prefrontal cortex: immunocytochemical and cognitive neuropharmacological analyses. Synapse 2003;47:101-108.
34. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
35. Folstein MF, Folstem SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189 -198.
36. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-281.
37. Owen AM, Evans AC, Petrides M. Evidence for a two-stage model of spatial working memory processing within the lateral frontal cortex: a positron emission tomography study. Cereb Cortex 1996; 6:31-38.
38. Owen AM, Doyon J, Petrides M, Evans AC. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 1996;8:353-364.
39. Beauchamp MH, Dagher A, Aston JA, Doyon J. Dynamic functional changes associated with cognitive skill learning of an adapted version of the Tower of London task. Neuroimage 2003; 20:1649-1660.
40. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994;63:972-979.
41. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 2001;432:119-136.
42. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002;22:389-395.
43. Matsumoto M, Weickert CS, Akil M, et al. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003; 116:127-137.
44. Gogos JA, Morgan M, Lume V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998; 95:9991-9996.
45. Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002; 15:246-256.
46. Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 1998;393:169-171.
47. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980;286:74-761.
48. Finlay JM, Zigmond MJ. The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res 1997;22:1387-1394.
49. Lipska BK, Weinberger DR. Prefrontal cortical and hippocampal modulation of dopamine-mediated effects. Adv Pharmacol 1998; 42:806-809.
50. Bray NJ, Buckland PR, Williams NM, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003;73: 152-161.